Abbott has entered into a commercial license agreement with Dowpharma for its Pfenex Expression Technology, a Pseudomonas-based technology for biologic production. Abbott’s product is a proprietary protein for which the company has already developed a high-yield production strain and a fully scalable process. Dow will transfer the production strain to Abbott and support its regulatory filing. Under the agreement, Abbott will have a non-exclusive license to use Pfenex for the development an...